Frequency Therapeutics Regenerative Med for Hearing Loss Fails Again in Phase 2
Frequency Therapeutics said its hearing loss drug candidate failed to beat a placebo in its second mid-stage clinical trial. The biotech is now focusing its regenerative medicine platform on the development of a multiple sclerosis drug not expected to reach the clinic until next year.
